Clinical Trials

Phase 1 Not yet recruiting

Pancreatic Neoplasms

NCT06699576 2024-11-21

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

448 enrolled

Phase 3 Active not recruiting

Sarcoma, Osteosarcoma

NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

528 enrolled

Advanced Renal Cancer

NCT05301764 2024-10-15

A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma

Phase 1/2 Recruiting

65 enrolled

NCT03866980 2024-04-03

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 3 Terminated

164 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02584478 2023-11-08

AL3818

294 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04325763 2022-03-31

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Phase 1/2 Unknown

90 enrolled

Gynecological Cancer

NCT04273815 2020-07-08

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Phase 1/2 Unknown

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

EndocrineGastrointestinalNET

150 enrolled

Digestive System Neoplasms, Neuroendocrine Tumors

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04291248 2020-03-02

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

138 enrolled

Other solid neoplasm

MSI-H or dMMR Advanced Solid Tumors

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

93 enrolled

Advanced Malignancy

NCT03825705 2019-10-31

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Phase 1/2 Unknown

Carcinoma, Hepatocellular

NCT03897283 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Phase 1 Unknown

22 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03910127 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04106024 2019-09-26

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04073550 2019-08-29

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

184 enrolled

Small Cell Lung Carcinoma

NCT02558348 2019-06-19

AL3818

Phase 1/2 Terminated

12 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01878448 2019-05-22

ALTN/STS

166 enrolled

Tumor-Agnostic

Neoplasms

NCT02825563 2019-05-22

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Phase 1 Completed

22 enrolled

Advanced Cancer

NCT01874873 2019-05-21

ALTN/MTC

58 enrolled

Tumor-Agnostic

Neoplasms

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

113 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase 2/3 Completed

91 enrolled

Carcinoma, Medullary

NCT03527888 2019-05-21

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

40 enrolled

Bone Neoplasms

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

120 enrolled

Small Cell Lung Carcinoma

NCT02622932 2019-04-30

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Phase 1 Completed

6 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02072044 2017-12-29

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Genitourinary

Carcinoma, Renal Cell

NCT02461407 2017-12-29

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

378 enrolled

Stomach Neoplasms

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

439 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02752516 2017-09-18

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Phase 1 Unknown

16 enrolled

Tumor-Agnostic

Neoplasms

NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

233 enrolled

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

110 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02809534 2016-09-07

ALTER0802

Carcinoma, Hepatocellular

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

117 enrolled